Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Beta-blocker

Therapeutic area intelligence for Beta-blocker with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 4

Companies

Beta-blocker →

Epic Pharma →

IPCA Labs Ltd. →

Assets

Recent signals(6)

RegulatoryAugust 3, 2026

FDA Approves Propranolol Hydrochloride Application ANDA203103

The FDA has approved the ANDA203103 application for Propranolol Hydrochloride submitted by IPCA Labs Ltd.

StrategyJuly 19, 2026

FDA Grants Approval for Nebivolol Hydrochloride ANDA212682

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 212682 for Nebivolol Hydrochloride submitted by Prinston Inc.

RegulatoryJuly 12, 2026

FDA Approves ANDA203103 for Propranolol Hydrochloride by IPCA Labs

The FDA has approved ANDA203103 for Propranolol Hydrochloride submitted by IPCA Labs.

StrategyJune 30, 2026

FDA Grants Approval for Propranolol Hydrochloride ANDA217238

The FDA has granted approval for the ANDA217238 application for Propranolol Hydrochloride submitted by Micro Labs.

RegulatoryJune 22, 2026

FDA Accepts Supplement for Labetalol Hydrochloride by Epic Pharma

The FDA has accepted a supplemental application for Labetalol Hydrochloride submitted by Epic Pharma.

StrategyJune 21, 2026

FDA Grants Approval for Propranolol Hydrochloride ANDA219165

The FDA has granted approval for the ANDA219165 application for Propranolol Hydrochloride submitted by PAI Holdings.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.